Creative Biolabs is one of the leading providers of custom antibody generation and development services for R&D, diagnostic, and therapeutic applications. Especially, we have launched a series of in vitro diagnostic (IVD) antibody development services targeting numerous diagnostic biomarkers of human cancer diseases. Here, we focus on the BRCA1 protein as a marker of ovarian cancer.
brca1 biomarker
Since the inception of Creative Biolabs, our research and service capacity has expanded to the entire new drug discovery and development pipeline, including early discovery, preclinical testing, process development, cGMP manufacturing, phase 1-III clinical trials. Stimuli-Responsive Liposome Development Service https://www.creative-biolabs.com/lipid-based-delivery/stimuli-responsive-liposome-development-service.htm
It is increasingly recognized that Bacteroides dorei (B. dorei) plays a pivotal role in the development of several kinds of diseases such as cardiovascular disease and metabolic disease. Creative Biolabs has rich experience in developing and producing live biotherapeutic products, with both aerobic and anaerobic organisms. We now provide customized B. dorei-based drug discovery services and products for global clients. Bacteroides dorei as Next Generation Probiotics https://live-biotherapeutic.creative-biolabs.com/bacteroides-dorei.htm
As a leading customer service provider in the field of antibody discovery and manufacturing, Creative Biolabs has expanded its reliable expertise and service capacity to the entire antibody exploration and development pipeline. Our cutting-edge hybridoma development and phage display platforms enable the production of the most comprehensive list of antibody products and extensive service portfolio at the most competitive price. anti-glutamate receptor antibodies services https://www.creative-biolabs.com/natural-autoantibody/naa-services-for-anti-glutamate-receptor-antibodies.htm
Decreased secretion of glucagon-like peptide 1 (GLP-1) may contribute to the development of obesity which is a major risk factor for the development of type 2 diabetes mellitus (T2DM). In non-alcoholic fatty liver disease, liver fat (triglyceride) accumulation closely mirrors adipose tissue dysfunction and insulin resistance in obesity and T2DM. Therefore, Creative Biolabs is working on the development of GLP-1 agonists to provide a novel choice for the treatment of NASH. We provide our clients with products and custom services to better serve NASH drug development. GLP-1 NASH https://www.creative-biolabs.com/nash-therapy/nash-target-development-service-for-glucagon-like-peptide-1-glp-1-agonists.htm